GECLID: una iniciativa de la Sociedad Española de Inmunología con beneficios para todos

Martín, María del Carmen; Reinoso, Roberto; Martino, Maria Carola; Corell, Alfredo

doi:10.1016/s0213-9626(11)70011-7

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the high‐resolution typing methods included PCR with sequence‐specific primers (SSP), PCR and hybridization with sequence‐specific oligoprobes (SSO), Sanger sequencing‐based typing (SBT) and, more recently, next‐generation sequencing (NGS). Supplementary information in Table S1 shows the percentage of the different HLA typing techniques used by Spanish laboratories since 2011, according to the data recorded by the External Quality Assurance Programme for diagnostic immunology laboratories (GECLID) of the Spanish Society for Immunology 24 …”

Section: Methodsmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high‐resolution analysis

Guerreiro

Planelles

Aguilar-Gallardo

et al. 2021

HLA

View full text Add to dashboard Cite

There are many studies on the polymorphism of the HLA system in healthy donor populations, such as registries of unrelated bone marrow donors. Investigations on the characterization of the HLA complex in hematopoietic stem cell transplant (HSCT) patients, however, are scarce, at least in the Spanish population. This study presents a large‐scale analysis of allelic diversity and HLA distribution at a high‐resolution level in 2886 patients undergoing HSCT in Spanish centres of the “Grupo Español de Trasplante Hematopoyético y Terapia Celular” during a period of 11 years. Allelic diversity analysis identified 67 HLA‐A, 133 HLA‐B, 60 HLA‐C, 63 HLA‐DRB1, 24 HLA‐DQB1 and 27 HLA‐DPB1 different alleles. Rare alleles were detected among which 33 alleles had not been reported in the European catalog of common and well‐documented HLA alleles. Regarding the distribution of five genes‐haplotypes, it was observed that the five most frequent extended haplotypes found in our population were between the most common in other Spanish populations, both in patients and in healthy subjects. However, some particular haplotypes were also detected. Bilocus associations HLA‐C ~ B and ‐DRB1 ~ DQB1 were analyzed in order to predict the probability of finding 10/10 matched donors in registries. We found HLA‐B alleles showing a great diversity of combinations with HLA‐C alleles and unusual associations involving a negative predicting factor. In the field of adoptive therapies, our work supports the necessity to expand further research of TCR‐engineered cells, adoptive transfer of virus‐specific T‐cells and vaccines to target HLA alleles other than A*02:01. HLA alleles such as A*01:01, A*03:01, A*24:02, B*44:03, B*07:02 or B*51:01, might be considered new targets due to its high frequency in our population.

show abstract

Section: Methodsmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high‐resolution analysis

Guerreiro

Planelles

Aguilar-Gallardo

et al. 2021

HLA

View full text Add to dashboard Cite

show abstract

“…The Spanish Society for Immunology founded in 1975 is a professional non-profit organization in Spain and is dedicated to promote and support excellence in research, scholarship, and clinical practice in immunology. The external quality assurance (EQA) program for diagnostic immunology laboratories (Garantía Externa de Calidad para Laboratorios de Inmunología Diagnóstica, GECLID) program was first run in 2011 ( Martín et al, 2011 ), and more than 130 laboratories all around the world take their interlaboratory comparisons for proficiency testing nowadays.…”

Section: Introductionmentioning

confidence: 99%

Analysis of immunogenetics interlaboratory comparisons’ success rates. External quality assurance system of the Spanish Society for Immunology GECLID-SEI

Martín

2024

Front. Genet.

View full text Add to dashboard Cite

Background:For many years, transplantation outcomes were uncertain and not hopeful, until histocompatibility testing spread. Common criteria for histocompatibility assays and communications’ improvement allowed an efficient organ sharing system. The possibility of organ exchanges is closely linked to the importance of interlaboratory comparisons for histocompatibility and immunogenetics methods. The external proficiency testing (EPT) systems are the most powerful quality assurance tools. They help achieve harmonization of analyses, set a standard of performance, and a common interpretation.Methods:The external quality assurance program for diagnostic immunology laboratories (Garantía Externa de Calidad para Laboratorios de Inmunología Diagnóstica, GECLID) program nowadays runs 13 external quality assurance (EQA) histocompatibility and immunogenetics schemes, with the first of them from 2011 to date: serological and molecular: low- and high-resolution human leukocyte antigen (HLA), human platelet antigen (HPA), and killer inhibitory receptor (KIR) typing(HLA-B*27, HLA-B*57:01, and coeliac disease-related HLA), cell-dependent cytotoxicity (CDC) and flow cytometry (FC) crossmatches, anti-HLA and anti-HPA antibodies, and chimerism.Results:A total of 85 laboratories participated in this subprogram in the last 12 years reporting over 1.69 M results: 1.46 M for anti-HLA and anti-HPA antibodies, 203.810 molecular typing data (HLA, HPA, and KIR genes), 2.372 for chimerism analyses, and 39.352 for crossmatches. Based on the European Federation for Immunogenetics (EFI) standards for EPT providers, the mean success rates ranged from 99.2% for molecular typing schemes and antibodies and 94.8% for chimerism, was 96.7% regarding crossmatches, and was 98.9% in serological typing. In 2022, 61.3% of the participating laboratories successfully passed every HLA EQA scheme, although 87.9% annual reports were satisfactory. Most penalties were due to nomenclature errors or misreporting of the risk associated to HLA and disease.Conclusion:This EQA confirms the reliability of HLA and immunogenetics assays in routine care. There is little heterogeneity of results of different assays used by participating laboratories, even when in-house assays are used. Reliability of test results is reasonably granted.

show abstract

GECLID: una iniciativa de la Sociedad Española de Inmunología con beneficios para todos

Cited by 2 publications

References 2 publications

Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high‐resolution analysis

Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high‐resolution analysis

Analysis of immunogenetics interlaboratory comparisons’ success rates. External quality assurance system of the Spanish Society for Immunology GECLID-SEI

Contact Info

Product

Resources

About